Mayne Pharma traded at 2.36 this Wednesday June 17th, increasing 0.01 or 0.43 percent since the previous trading session. Looking back, over the last four weeks, Mayne Pharma gained 1.72 percent. Over the last 12 months, its price fell by 55.81 percent. Looking ahead, we forecast Mayne Pharma to be priced at 2.36 by the end of this quarter and at 2.22 in one year, according to Trading Economics global macro models projections and analysts expectations.
Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company. The Company is focused on commercializing generic pharmaceuticals. The Company operates through three segments: International, Branded Products Division (BPD) and Portfolio Products Division (PPD). Its International segment manufactures and sells branded and generic pharmaceutical product globally and the provision of contract development and manufacturing services to third party customers. The BPD segment distributes medically differentiated specialty products in United States. The PPD segment distributes established products (branded and generic) in the United States on a portfolio basis. The Company's products include Doxycycline Capsules, Oxycodone IR Tablets, Erythromycin Capsules and others.